

Gene-expression profiling and not immunophenotypic patients with diffuse large B-cell lymphoma treated with

Blood

117, 4836-4843

DOI: [10.1182/blood-2010-12-322362](https://doi.org/10.1182/blood-2010-12-322362)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New developments in the pathology of malignant lymphoma. A review of the literature published from February 2011 to August 2011. <i>Journal of Hematopathology</i> , 2011, 4, 135-144.	0.2	0
2	Aggressive B-Cell Lymphomas: A Review of New and Old Entities in the WHO Classification. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 506-514.	0.9	92
3	B Cells Behaving Badly: A Better Basis to Behold Belligerence in B-Cell Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 330-335.	0.9	6
4	BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab. <i>Clinical Cancer Research</i> , 2011, 17, 7785-7795.	3.2	152
5	Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions. <i>OncoTargets and Therapy</i> , 2012, 5, 433.	1.0	6
6	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3452-3459.	0.8	824
7	The contribution of HGAL/GCET2 in immunohistological algorithms: a comparative study in 424 cases of nodal diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2012, 25, 1439-1445.	2.9	5
8	Activity and complexes of mTOR in diffuse large B-cell lymphomas—a tissue microarray study. <i>Modern Pathology</i> , 2012, 25, 1623-1628.	2.9	21
9	Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 34-42.	0.6	40
10	Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 2159-2165.	0.6	47
11	Diagnosis and treatment of diffuse large B-cell lymphoma. <i>Swiss Medical Weekly</i> , 2012, 142, w13511.	0.8	27
12	Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?. <i>Oncologist</i> , 2012, 17, 1562-1573.	1.9	41
13	Molecular Profiling of Aggressive Lymphomas. <i>Advances in Hematology</i> , 2012, 2012, 1-9.	0.6	3
14	Advances in the diagnosis and management of lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, , 29.	1.2	3
15	The Histological and Biological Spectrum of Diffuse Large B-Cell Lymphoma in the World Health Organization Classification. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 411-420.	1.0	102
16	Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. <i>British Journal of Haematology</i> , 2012, 159, 441-453.	1.2	81
17	Role of Positron Emission Tomography with Fludeoxyglucose F 18 in Personalization of Therapy in Patients with Lymphoma. <i>PET Clinics</i> , 2012, 7, 57-65.	1.5	2
18	A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. <i>Haematologica</i> , 2012, 97, 758-765.	1.7	153

#	ARTICLE	IF	CITATIONS
19	Double-Hit Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3439-3443.	0.8	81
20	Microarray Gene Expression Analysis of Fixed Archival Tissue Permits Molecular Classification and Identification of Potential Therapeutic Targets in Diffuse Large B-Cell Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 223-232.	1.2	24
21	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Leukemia</i> , 2012, 26, 2103-2113.	3.3	301
22	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 120, 2290-2296.	0.6	53
23	Diffuse Large B-Cell Lymphoma of the Orbit: Clinicopathologic, Immunohistochemical, and Prognostic Features of 20 Cases. <i>American Journal of Ophthalmology</i> , 2012, 154, 87-98.e1.	1.7	37
24	The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. <i>British Journal of Cancer</i> , 2012, 107, 1423-1432.	2.9	17
25	CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy. <i>Annals of Hematology</i> , 2012, 91, 1897-1906.	0.8	18
26	Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2012, 1, 2.	2.0	27
27	Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 763-769.	0.6	15
28	Treatment of Diffuse Large B Cell Lymphoma. <i>Korean Journal of Internal Medicine</i> , 2012, 27, 369.	0.7	24
29	Molecular genetic characterization of lymphoma: Application to cytology diagnosis. <i>Diagnostic Cytopathology</i> , 2012, 40, 542-555.	0.5	21
30	Prospective nested case-control study of feature genes related to leukemic evolution of myelodysplastic syndrome. <i>Molecular Biology Reports</i> , 2013, 40, 469-476.	1.0	11
31	Cancer Genomics. , 2013, , .		4
32	Actualit�s th�rapeutiques dans les lymphomes. , 2013, , .		0
33	Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients. <i>Histopathology</i> , 2013, 63, 788-801.	1.6	25
34	Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: An investigation of clinical and histopathological features. <i>Acta Ophthalmologica</i> , 2013, 91, 1-27.	0.6	37
35	Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. <i>Cancer Genetics</i> , 2013, 206, 257-265.	0.2	21
36	ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. <i>Modern Pathology</i> , 2013, 26, 1329-1337.	2.9	50

#	ARTICLE	IF	CITATIONS
37	Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment. <i>Leukemia and Lymphoma</i> , 2013, 54, 1934-1941.	0.6	18
38	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	0.6	193
39	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	0.6	596
40	Bcl-6 expression and lactate dehydrogenase level predict prognosis of primary gastric diffuse large B-cell lymphoma. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 382-389.	0.8	15
41	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	0.6	206
42	ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type. <i>Leukemia Research</i> , 2013, 37, 3-8.	0.4	6
43	MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Haematologica</i> , 2013, 98, 1554-1562.	1.7	196
45	Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 43-57.	1.1	18
46	Primary Diffuse Large B-Cell Lymphoma of the Ascending Colon. <i>Rare Tumors</i> , 2013, 5, 85-88.	0.3	22
47	Gene Profiling of Canine B-Cell Lymphoma Reveals Germinal Center and Postgerminal Center Subtypes with Different Survival Times, Modeling Human DLBCL. <i>Cancer Research</i> , 2013, 73, 5029-5039.	0.4	118
48	Aggressive B-cell lymphomas: how many categories do we need?. <i>Modern Pathology</i> , 2013, 26, S42-S56.	2.9	47
49	Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies. <i>Clinical Cancer Research</i> , 2013, 19, 6686-6695.	3.2	115
50	CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 87-92.	1.2	19
51	The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. <i>American Journal of Hematology</i> , 2013, 88, 1062-1067.	2.0	54
52	MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2149-2154.	0.6	16
53	CD4 ⁺ Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemotherapy. <i>American Journal of Hematology</i> , 2013, 88, 273-276.	2.0	71
54	III. Applying molecular phenotyping in practice. <i>Hematological Oncology</i> , 2013, 31, 29-32.	0.8	6
55	Molecular Profiling Reveals Prognostically Significant Subtypes of Canine Lymphoma. <i>Veterinary Pathology</i> , 2013, 50, 693-703.	0.8	95

#	ARTICLE	IF	CITATIONS
56	Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma. <i>Blood Research</i> , 2013, 48, 266.	0.5	16
57	Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis. <i>Current Biomarker Findings</i> , 0, , 17.	0.4	1
58	Immunohistochemical and Molecular Characteristics with Prognostic Significance in Diffuse Large B-Cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e98169.	1.1	31
59	Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and -uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era. <i>Leukemia and Lymphoma</i> , 2014, 55, 551-557.	0.6	24
60	p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression. <i>American Journal of Clinical Pathology</i> , 2014, 141, 593-604.	0.4	46
61	Young Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. <i>Journal of Clinical Oncology</i> , 2014, 32, 3996-4003.	0.8	79
62	Adolescents and Young Adults with Non-Hodgkin's Lymphoma: Slipping between the Cracks. <i>Acta Haematologica</i> , 2014, 132, 279-291.	0.7	5
63	Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2688-2693.	1.1	4
64	High Concordance of Gene Expression Profiling-correlated Immunohistochemistry Algorithms in Diffuse Large B-cell Lymphoma, Not Otherwise Specified. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1046-1057.	2.1	33
65	Fatal Necrotizing Angiotropic Epstein-Barr Virus-negative Large B-cell Lymphoma. <i>Medicine (United Tj ETQq1 1 0.784314 1gBT /Over</i>	0.4	1
66	Genetics of Diffuse Large B-Cell Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 43-47.	1.0	4
67	Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2014, 38, 694-698.	0.4	39
68	Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 460-467.e2.	0.2	86
69	Gene expression analysis in RA: towards personalized medicine. <i>Pharmacogenomics Journal</i> , 2014, 14, 93-106.	0.9	65
70	A treatment for activated B-cell-like DLBCL?. <i>Lancet Oncology, The</i> , 2014, 15, 916-917.	5.1	2
71	Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype. <i>Clinical Cancer Research</i> , 2014, 20, 5182-5193.	3.2	34
72	Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. <i>Annals of Hematology</i> , 2014, 93, 1867-1877.	0.8	16
73	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014, 123, 1214-1217.	0.6	518

#	ARTICLE	IF	CITATIONS
74	Pathology Consultation on Intermediate-to-Large B-Cell Lymphomas. American Journal of Clinical Pathology, 2014, 141, 305-317.	0.4	7
75	Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood, 2015, 126, 1893-1901.	0.6	117
76	Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. Journal of Hematology and Oncology, 2015, 8, 70.	6.9	28
77	Reply to M. Gleeson et al. Journal of Clinical Oncology, 2015, 33, 3216-3217.	0.8	1
78	Aggressive B-Cell Lymphomas. Advances in Anatomic Pathology, 2015, 22, 168-180.	2.4	9
79	Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e458-e466.	1.8	47
80	The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma. PLoS ONE, 2015, 10, e0126615.	1.1	22
81	Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 2039-2046.	0.6	12
82	Genetic lesions in diffuse large B-cell lymphomas. Annals of Oncology, 2015, 26, 1069-1080.	0.6	65
83	The Histological Classification of Diffuse Large B-cell Lymphomas. Seminars in Hematology, 2015, 52, 57-66.	1.8	67
84	Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities?. Annals of Hematology, 2015, 94, 609-616.	0.8	7
85	When and how to test for C-MYC in aggressive B cell lymphomas. Journal of Hematopathology, 2015, 8, 13-20.	0.2	2
86	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. Journal of Clinical Oncology, 2015, 33, 2848-2856.	0.8	334
87	Identification and validation of a two-gene expression index for subtype classification and prognosis in Diffuse Large B-Cell Lymphoma. Scientific Reports, 2015, 5, 10006.	1.6	15
88	Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay. Journal of Molecular Diagnostics, 2015, 17, 273-283.	1.2	50
89	Peripheral Blood Lymphocyte/Monocyte Ratio Predicts Outcome in Follicular Lymphoma and in Diffuse Large B-Cell Lymphoma Patients in the Rituximab Era. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 208-213.	0.2	35
90	Immunohistochemical prognostication in diffuse large B-cell lymphoma: a single center 6-year retrospective analysis. Leukemia and Lymphoma, 2015, 56, 2975-2977.	0.6	1
91	Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma. Seminars in Hematology, 2015, 52, 107-118.	1.8	16

#	ARTICLE	IF	CITATIONS
92	Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a "String". Clinical Cancer Research, 2015, 21, 2204-2206.	3.2	1
93	Machine Learning-based Classification of Diffuse Large B-cell Lymphoma Patients by Their Protein Expression Profiles. Molecular and Cellular Proteomics, 2015, 14, 2947-2960.	2.5	73
94	A modified scoring of the <scp>NCCN</scp> "IPI" is more accurate in the elderly and is improved by albumin and β_2 -microglobulin. British Journal of Haematology, 2015, 168, 239-245.	1.2	69
95	Next-generation prognostic assessment for diffuse large B-cell lymphoma. Future Oncology, 2015, 11, 2443-2457.	1.1	8
96	Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. Experimental and Molecular Pathology, 2015, 99, 537-545.	0.9	13
97	Caution in the Use of Immunohistochemistry for Determination of Cell of Origin in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2015, 33, 3215-3216.	0.8	7
98	Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCHR) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. British Journal of Haematology, 2015, 169, 188-198.	1.2	49
99	Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR. Laboratory Investigation, 2015, 95, 113-120.	1.7	17
100	Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma. Blood Research, 2016, 51, 113.	0.5	12
101	Cytogenetics in the management of lymphomas and lymphoproliferative disorders in adults and children: an update by the Groupe francophone de cytogénétique hématologique (GFCH). Annales De Biologie Clinique, 2016, 74, 568-587.	0.2	3
102	Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update. F1000Research, 2016, 5, 1933.	0.8	8
103	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget, 2016, 7, 18036-18049.	0.8	26
104	Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma. Nuclear Medicine Communications, 2016, 37, 689-698.	0.5	15
105	Sphingosine-1-phosphate receptor 1 as a prognostic biomarker and therapeutic target for patients with primary testicular diffuse large B-cell lymphoma. British Journal of Haematology, 2016, 174, 264-274.	1.2	13
106	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncology, 2016, 12, 1553-1563.	1.1	85
107	The distinct clinical features and prognosis of the CD10 ⁺ MUM1 ⁺ and CD10 ⁻ Bcl6 ⁺ MUM1 ⁻ diffuse large B-cell lymphoma. Scientific Reports, 2016, 6, 20465.	1.6	22
108	An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL. Blood, 2016, 128, 2797-2807.	0.6	48
109	Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era. Nuclear Medicine Communications, 2016, 37, 1095-1101.	0.5	15

#	ARTICLE	IF	CITATIONS
110	Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas. <i>Surgical Pathology Clinics</i> , 2016, 9, 41-54.	0.7	5
111	Concurrent Elevations of VEGF, Osteopontin and MCP-1 Serum Levels Are Independent Predictors of Survival in Patients with Diffuse Large B-Cell Lymphoma. <i>Acta Haematologica</i> , 2016, 136, 52-61.	0.7	34
113	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 4015-4022.	0.8	66
114	EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016, 91, 529-537.	2.0	74
115	Molecular Classification of Diffuse Large B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1163-1177.	0.9	22
116	Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1093-1102.	1.5	3
117	Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β_2 -microglobulin level in patients with diffuse large B-cell lymphoma: a new prognostic model. <i>British Journal of Haematology</i> , 2016, 175, 290-299.	1.2	31
118	Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 961-967.	0.8	8
119	Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis. <i>Clinica Chimica Acta</i> , 2016, 463, 47-52.	0.5	7
120	The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. <i>Annals of Hematology</i> , 2016, 95, 1491-1501.	0.8	9
121	A Clinician's Approach to Double-Hit Lymphoma: Identification, Evaluation, and Management. <i>Journal of Oncology Practice</i> , 2016, 12, 232-238.	2.5	9
122	Molecular subtyping of diffuse large B-cell lymphoma: update on biology, diagnosis and emerging platforms for practising pathologists. <i>Pathology</i> , 2016, 48, 5-16.	0.3	8
123	Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3801-3809.	3.2	151
124	High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2016, 95, 253-262.	0.8	19
125	High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy. <i>International Journal of Hematology</i> , 2016, 103, 210-218.	0.7	8
126	TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma. <i>Histopathology</i> , 2017, 71, 98-111.	1.6	42
127	Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 623-632.	1.5	2
128	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. <i>Annals of Oncology</i> , 2017, 28, 1042-1049.	0.6	21

#	ARTICLE	IF	CITATIONS
129	DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. <i>Pathology</i> , 2017, 49, 731-739.	0.3	15
130	Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 892-904.	1.2	39
131	Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?. <i>Expert Review of Hematology</i> , 2017, 10, 761-774.	1.0	14
132	A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib. <i>Blood</i> , 2017, 130, 1676-1679.	0.6	26
133	Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 783-796.	0.2	29
134	Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-intense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation. <i>British Journal of Haematology</i> , 2017, 178, 927-935.	1.2	8
135	Radiation Therapy in Hematologic Malignancies. , 2017, , .		0
136	BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy. <i>Veterinary and Comparative Oncology</i> , 2017, 15, 1269-1279.	0.8	18
137	The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions. <i>Leukemia and Lymphoma</i> , 2017, 58, 1178-1183.	0.6	1
138	Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2017, 96, 1-8.	0.8	32
139	Mutational profile of primary breast diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 102888-102897.	0.8	22
140	Succeeding in Breaking the R-CHOP Ceiling in DLBCL: Learning From Negative Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3519-3522.	0.8	28
141	Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2515-2526.	0.8	179
142	Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm. <i>Oncotarget</i> , 2017, 8, 22014-22022.	0.8	40
143	CAR T cell therapy for B-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 135-146.	0.7	39
144	Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 680-688.	3.3	72
145	Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 91-97.	0.2	4
146	Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma—a feasibility study using full slide staining. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 341-349.	1.4	5

#	ARTICLE	IF	CITATIONS
147	Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. <i>Blood Reviews</i> , 2018, 32, 400-415.	2.8	49
148	Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts. <i>British Journal of Haematology</i> , 2018, 181, 272-275.	1.2	8
149	Molecular classification of tumour cells in a patient with intravascular large B-cell lymphoma. <i>British Journal of Dermatology</i> , 2018, 178, 215-221.	1.4	14
150	The price of success-health economics of personalized diffuse large B-cell lymphoma treatment. <i>Leukemia and Lymphoma</i> , 2018, 59, 1517-1519.	0.6	1
151	Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia. <i>Journal of Clinical Pathology</i> , 2018, 71, 215-220.	1.0	13
152	Molecular Hematopathology. , 2018, , 712-760.e18.		4
153	Epidemiologic characteristics of malignant lymphoma in Hubei, China. <i>Medicine (United States)</i> , 2018, 97, e12120.	0.4	22
154	Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2018, 09, .	0.4	7
155	Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	2
156	Genetic Aspects of Hematopoietic Malignancies. , 2018, , 201-234.		1
157	FISH studies in DLBCL: correlations with cell of origin: the Irish experience. <i>Journal of Clinical Pathology</i> , 2018, 71, 947-948.	1.0	2
158	An update on high grade B-cell lymphoma. <i>Diagnostic Histopathology</i> , 2018, 24, 237-245.	0.2	1
159	The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. <i>Annals of Hematology</i> , 2018, 97, 2363-2372.	0.8	13
160	The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis. <i>Annals of Hematology</i> , 2018, 97, 2137-2144.	0.8	11
161	Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma. <i>Journal of Translational Medicine</i> , 2018, 16, 162.	1.8	17
162	Differential prognostic impact of <sc>GELTAMO</sc>â€<sc>IPI</sc> in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm. <i>British Journal of Haematology</i> , 2018, 182, 534-541.	1.2	7
163	Dissecting aggressive B-cell lymphoma through genomic analysis â€“ What is clinically relevant?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 187-198.	0.7	2
164	Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 356-368.	1.2	14

#	ARTICLE	IF	CITATIONS
165	A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 513-518.	1.4	13
166	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019, 134, 1289-1297.	0.6	26
167	Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact. <i>Journal of Clinical Medicine</i> , 2019, 8, 1074.	1.0	6
168	Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature. <i>Expert Review of Hematology</i> , 2019, 12, 1095-1105.	1.0	5
169	A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas. <i>PLoS ONE</i> , 2019, 14, e0223260.	1.1	4
171	Molecular Profiles of Cell-to-Cell Variation in the Regenerative Potential of Mesenchymal Stromal Cells. <i>Stem Cells International</i> , 2019, 2019, 1-14.	1.2	24
172	Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 959-973.	1.0	18
173	Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 572-580.	0.6	17
174	Genetic alterations and their clinical implications in DLBCL. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 634-652.	12.5	136
175	Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL. <i>Journal of Translational Medicine</i> , 2019, 17, 198.	1.8	8
176	Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin. <i>Journal of Global Oncology</i> , 2019, 5, 1-8.	0.5	3
177	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 48.	2.8	24
178	Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma—an analysis of 386 Portuguese patients. <i>Annals of Hematology</i> , 2019, 98, 1937-1946.	0.8	4
179	Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. <i>Frontiers in Oncology</i> , 2019, 9, 107.	1.3	34
180	Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e307-e311.	0.2	5
181	Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. <i>American Journal of Hematology</i> , 2019, 94, 604-616.	2.0	307
182	The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients. <i>International Journal of Cancer</i> , 2019, 145, 2459-2467.	2.3	7
183	Lymphomas of the head and neck region: an update. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 649-665.	1.4	24

#	ARTICLE	IF	CITATIONS
184	Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 50-56.	0.1	2
185	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. <i>Blood Advances</i> , 2019, 3, 2013-2021.	2.5	40
186	Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma. <i>Surgical Pathology Clinics</i> , 2019, 12, 699-707.	0.7	13
187	A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF- κ B-double-targeting to molecularly assess therapy response. <i>International Journal of Hematologic Oncology</i> , 2019, 8, IJH20.	0.7	7
188	Effect of oral magnesium sulfate administration on blood glucose hemostasis via inhibition of gluconeogenesis and FOXO1 gene expression in liver and muscle in diabetic rats. <i>Biomedicine and Pharmacotherapy</i> , 2019, 109, 1819-1825.	2.5	10
189	Current lymphoma diagnostic standards: the pathologists'™ view. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 17-23.	0.3	1
190	Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 1-16.	2.0	9
191	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091.	0.6	6
192	Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns. <i>Leukemia Research</i> , 2019, 76, 107-111.	0.4	6
193	A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. <i>Leukemia</i> , 2020, 34, 543-552.	3.3	26
194	Non-Hodgkin Lymphomas. , 2020, , 1926-1947.e5.		0
195	Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 176-183.	0.9	33
196	New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta α 2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). <i>British Journal of Haematology</i> , 2020, 188, 888-897.	1.2	40
197	Primary Colonic Lymphoma With Paraneoplastic Hypercalcemia. <i>ACG Case Reports Journal</i> , 2020, 7, e00439.	0.2	0
198	A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise. <i>Lancet Haematology</i> , 2020, 7, e838-e850.	2.2	12
199	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020, 4, 3391-3404.	2.5	22
200	Diffuse Large B-Cell Lymphoma's™ New Genomics: The Bridge and the Chasm. <i>Journal of Clinical Oncology</i> , 2020, 38, 3565-3574.	0.8	16
201	Platform independent protein-based cell-of-origin subtyping of diffuse large B-cell lymphoma in formalin-fixed paraffin-embedded tissue. <i>Scientific Reports</i> , 2020, 10, 7876.	1.6	4

#	ARTICLE	IF	CITATIONS
202	Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a qPCR-based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded Tissues. <i>Frontiers in Oncology</i> , 2020, 10, 803.	1.3	10
203	Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 1267-1281.	7.7	40
204	<i>MYC</i> rearrangement and <i>MYC/BCL2</i> double expression but not cell-of-origin predict prognosis in R-CHOP-treated diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 336-343.	1.1	15
205	Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies. <i>Translational Medicine Communications</i> , 2020, 5, .	0.5	11
206	Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 284-294.	1.1	12
207	Primary pancreatic diffuse large B-cell lymphoma, activated B-cell subtype, diagnosed by endoscopic ultrasound-guided fine needle aspiration: A case report and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 669-672.	0.2	1
208	Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110139.	1.1	11
209	Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198957.	1.1	9
210	Acute orbital presentation in an activated B-cell subtype, diffuse large B-cell lymphoma: clinicoradiological, histopathological and immunohistochemical correlation. <i>Indian Journal of Ophthalmology Case Reports</i> , 2021, 1, 608.	0.0	0
211	Role of MUM-1 immunohistochemistry in prognosis of primary gastrointestinal diffuse large cell lymphoma. <i>Indian Journal of Pathology and Oncology</i> , 2021, 8, 75-78.	0.1	1
212	A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma. <i>Med</i> , 2021, 2, 180-195.e5.	2.2	0
213	Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 323-340.	1.2	2
214	Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas. <i>Cells</i> , 2021, 10, 675.	1.8	10
215	2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. <i>American Journal of Hematology</i> , 2021, 96, 617-629.	2.0	145
216	Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma. <i>Nuclear Medicine Communications</i> , 2021, 42, 792-799.	0.5	2
217	High Expression of Caspase-8 Associated with Improved Survival in Diffuse Large B-Cell Lymphoma: Machine Learning and Artificial Neural Networks Analyses. <i>BioMedInformatics</i> , 2021, 1, 18-46.	1.0	14
218	DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set. <i>Scientific Data</i> , 2021, 8, 135.	2.4	11
219	Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients. <i>Bioscience Reports</i> , 2021, 41, .	1.1	0

#	ARTICLE	IF	CITATIONS
220	Testicular Diffuse Large B-Cell Lymphoma—Clinical, Molecular, and Immunological Features. <i>Cancers</i> , 2021, 13, 4049.	1.7	11
221	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1361-1369.	0.6	4
222	Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL. <i>Annals of Nuclear Medicine</i> , 2021, 35, 24-30.	1.2	14
223	Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 731-740.	0.6	7
224	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 402-9.	0.9	44
225	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 402-409.	0.9	48
226	Dissecting diffuse large B-cell lymphomas of the “not otherwise specified” type: the impact of molecular techniques. <i>F1000Research</i> , 2018, 7, 1966.	0.8	2
227	Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. <i>Drugs of Today</i> , 2020, 56, 287.	0.7	5
228	A Microarray Platform-Independent Classification Tool for Cell of Origin Class Allows Comparative Analysis of Gene Expression in Diffuse Large B-cell Lymphoma. <i>PLoS ONE</i> , 2013, 8, e55895.	1.1	64
229	MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. <i>PLoS ONE</i> , 2014, 9, e104068.	1.1	39
230	Machine Learning Provides an Accurate Classification of Diffuse Large B-Cell Lymphoma from Immunohistochemical Data. <i>Journal of Pathology Informatics</i> , 2018, 9, 21.	0.8	7
231	Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 224-241.	0.4	12
232	Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland. <i>Swiss Medical Weekly</i> , 2013, 143, w13748.	0.8	10
233	The Current Lymphoma Classification: New Concepts and Practical Applications—Triumphs and Woes. <i>Annals of Saudi Medicine</i> , 2012, 32, 296-305.	0.5	6
234	A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL. <i>Blood Advances</i> , 2022, 6, 2388-2402.	2.5	8
235	Where Do We Stand in the Genomics of Lymphomas?. , 2013, , 495-541.		0
236	Lymphome diffus Å grandes cellules B. , 2013, , 65-81.		0
237	Lymphomas. , 2013, , 962-974.		0

#	ARTICLE	IF	CITATIONS
238	Association Between the Immunohistochemical GCB/non GCB Classification and the Outcome of the Patient With Diffuse Large B - Cell Lymphoma Treated With Rituximab - CHOP Regimen: Single Centre Experience. <i>Journal of Internal Medicine Research</i> , 2013, 1, 3.	0.3	1
239	Germinal-center type B-cell classification and clinical characteristics of Chinese pediatric diffuse large B-cell lymphoma: a report of 76 cases. <i>Chinese Journal of Cancer</i> , 2013, 32, 561-566.	4.9	0
241	Benign and Malignant Lymphoid Lesions of the Head and Neck. , 2016, , 579-611.		0
242	Diffuse Large B-Cell Lymphoma. , 2017, , 29-43.		0
243	Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes. <i>Journal of Hematology (Brossard, Quebec)</i> , 2017, 6, 33-43.	0.4	5
244	Case report. A rare case of triple-hit diffuse large B-cell lymphoma of the parotid gland in a patient with Sjogrenâ€™s syndrome. <i>Romanian Journal of Rhinology</i> , 2017, 7, 103-107.	0.1	0
245	GroÃžzellige und aggressive B-Zell Lymphome. , 2019, , 601-624.		0
246	Clinical and Prognostic Value of Molecular Markers of Diffuse Large B-Cell Lymphoma. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2019, 12, 95-100.	0.1	4
248	The prognostic importance of double-expressor subgroup and AID , UNG and mismatch repair protein expressions in diffuse large B-cell lymphomas. <i>Marmara Medical Journal</i> , 0, , .	0.2	0
249	Non-Hodgkin's Lymphoma: What Matters Tumor Type or Burden?. <i>Journal of Postgraduate Medicine Education and Research</i> , 2020, 54, 69-76.	0.1	0
250	DA-REPOCH Versus R-CHOP for the Treatment of Activated B-Cell Subtype Diffuse Large B-Cell Lymphoma: A Community Center Experience. <i>Cureus</i> , 2020, 12, e11714.	0.2	2
251	Lymph nodes and spleen. , 2015, , 688-812.		1
252	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 245-52.	0.4	7
253	Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 15173-81.	1.3	25
254	Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 789-798.	0.6	12
255	Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment. <i>Oncologist</i> , 2022, 27, 57-66.	1.9	4
256	Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice. <i>Current Oncology Reports</i> , 2022, 24, 13-21.	1.8	15
257	Clinicopathologic features and outcomes of diffuse large B-cell lymphoma with extranodal involvement: A retrospective analysis. <i>Cancer Research Statistics and Treatment</i> , 2022, 5, 67.	0.1	0

#	ARTICLE	IF	CITATIONS
258	Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma. <i>Pathology Research and Practice</i> , 2022, 231, 153804.	1.0	3
259	Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Endocrinology</i> , 2022, 13, 846357.	1.5	5
262	New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1848-1858.	0.5	5
263	ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Reviews</i> , 2022, 56, 100967.	2.8	2
264	An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy. <i>EJHaem</i> , 2022, 3, 722-733.	0.4	1
265	Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
266	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics. <i>Disease Markers</i> , 2022, 2022, 1-16.	0.6	1
267	Risk-stratification in diffuse large B-cell lymphoma in the rituximab era. <i>Medicinski Pregled</i> , 2022, 75, 82-87.	0.1	0
268	Extracellular Vesicles in Diffuse Large B Cell Lymphoma: Characterization and Diagnostic Potential. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13327.	1.8	4
269	Potential Prognostic and Predictive Role of Monocyte and Lymphocyte Counts on Presentation in Patients Diagnosed With Diffuse Large B-Cell Lymphoma. <i>Cureus</i> , 2023, , .	0.2	1
270	Clinical and laboratory diversity of diffuse large B-cell lymphomas in children with Nijmegen breakage syndrome. <i>Haematologica</i> , 0, , .	1.7	0